Dual Force Immunotherapy for CLL
Chronic Lymphocytic Leukemia
Phase 2Active
Key Facts
About ViferaXS
ViferaXS is a Munich-based biotech founded in 2018, developing 'Dual Force' off-the-shelf immunotherapies for cancer. Its core technology platform rapidly identifies naturally presented tumor antigens from patient samples and pairs them with a proprietary adjuvant, XS15, to induce potent T-cell responses. The company has a Phase II-ready program in Chronic Lymphocytic Leukemia (CLL) and is seeking partnerships to advance its pipeline in hematologic and solid tumors.
View full company profileTherapeutic Areas
Other Chronic Lymphocytic Leukemia Drugs
| Drug | Company | Phase |
|---|---|---|
| P-001 | Panacea Biotec | Phase 2 |
| clonoSEQ (CLL, Blood/BM) | Adaptive Biotechnologies | FDA-Cleared |